Option chain shows key data for Pluri's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Pluri.

Pluri (NASDAQ:PLUR) Stock, Option Chain

Pluri

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.

Equities

News

Penny Stocks

Health Care

Contracts

Markets

General

PLUR

Pluri Inc. (NASDAQ: PLUR) has signed a three-year, $4.2 million contract with the U.S.

Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome

Pluri Inc

PLURAL INDUSTRY HLDG GRP by Plural Industry Holding Group Co. Limited

Plural Industry Holding Group Co Ltd

Pluribus Technologies Corp

Plurilock Security Inc

Plurilock Security Inc Ordinary Shares

Press Releases

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

Small Cap

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Biotech

Events

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Financing

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

BCLI

Abpro Hldgs

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CEL-SCI

Elevation Oncology

Equillium

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

OS Therapies

Ovid Therapeutics

Passage Bio

Q32 Bio

Rallybio

RenovoRx

Tenaya Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

Exicure

Comments

Pluri

Pluri (PLUR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga